China Approves Subcutaneous Formulation of LEQEMBI for Early Alzheimer's Disease

China's National Medical Products Administration (NMPA) has approved the subcutaneous autoinjector formulation of LEQEMBI (lecanemab) as an initiation treatment for mild cognitive impairment or mild dementia due to Alzheimer's disease. This regulatory action introduces a new, convenient option for once-weekly, at-home administration of the anti-amyloid beta protofibril antibody, complementing the existing intravenous treatment.